Denis A. Fedorenko's research while affiliated with Ministry Of Health Of The Russian Federation and other places

Publications (69)

Article
Secondary autoimmune diseases (2ndADs), most frequently autoimmune cytopenias (AICs), were first described after allogeneic hematopoietic stem cell transplantation (HSCT) undertaken for malignant and hematological indications, occurred at a prevalence of ~5–6.5%, and were attributed to allogeneic immune imbalances in the context of graft versus hos...
Article
Full-text available
Aim. To assess the long-term results of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) for multiple myeloma (MM) in the real setting and influence of different factors on the results. Materials and methods. From 2006 till 2018 in Pirogovs Center were performed 205 autoHSCT for patients with MM, aged...
Article
Full-text available
Aim. Comparative efficacy analysis of autologous hematopoietic stem cells (HSC) prior to auto-HSCT in patients with lymphoproliferative disorders (LPDs) and multiple sclerosis (MS). Materials & Methods. The trial included 237 patients: 103 LPD and 134 MS patients. In 225 patients HSC mobilization involved only colony-stimulating factors (CSFs), in...
Article
Full-text available
Autologous hematopoietic stem cell transplantation (HSCT), a safer type of HSCT than allogeneic HSCT, is a promising therapy for patients with severe autoimmune diseases (ADs). Despite the long history of medical practice, structural changes in the adaptive immune system as a result of autologous HSCT in patients with various types of ADs remain po...
Article
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is a promising approach to treatment of multiple sclerosis (MS) patients. In this paper, we present the long-term outcomes of a prospective single-center study with the analysis of the safety and efficacy of HDIT + AHSCT with reduced-intensity...
Article
Full-text available
Multiple sclerosis (MS) is a major inflammatory and demyelinating disease of the central nervous system (CNS), associated with a broad spectrum of physical, psychological, and social impairments. High-dose immunosuppressive therapy (HDIT) with autologous haematopoietic stem cell transplantation (AHSCT) is a new and promising approach to MS treatmen...
Article
Information about the efficacy and safety of the second-line therapy with dasatinib in patients in chronic phase chronic myeloid leukemia (CML-CP) at long-term follow-up is limited. Evaluation of benefits and risks of the treatment in a “real-world” study both from physician’s and patient’s perspective is worthwhile to better define treatment outco...
Article
Full-text available
Currently high-doses chemotherapy (HD-PCT) + autologous hematopoietic stem cells transplantation (auto-HSCT) is the treatment ofchoice in patients with recurrent and progressive lymphomas. Most of quality of life (QoL) studies in lymphomas patients received HSCT limited on parameters dynamics assessment in the early and late post-transplant period....
Article
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (autoSCT) is a treatment of choice for patients who relapse after first CR or with ineffectiveness of conventional chemotherapy. The goal of this study was to evaluate the effectiveness of HDCT with autoSCT in patients with Hodgkin lymphoma according to the response criteria fo...
Article
There is limited published data about the efficacy and safety of the second-line therapy with dasatinib in patients in chronic phase chronic myeloid leukemia (CML-CP) in a “real world” patients setting outside clinical trials. In addition, comprehensive evaluation of benefits and risks of the treatment is worthwhile to better define treatment outco...
Article
4445 Despite remarkable responses with imatinib in chronic phase chronic myeloid leukemia (CML-CP), there remains a proportion of patients who are resistant or intolerant to imatinib treatment. Dasatinib is effective second-line treatment for this patient population. Importantly, without effective therapeutic intervention, these patients inevitably...
Article
High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. In this article, we present the results of a prospective phase II open-label single-center study with the analysis of the safety and efficacy of high-dose immunosuppressive therapy...
Article
Full-text available
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.
Article
Full-text available
Autologous haematopoietic stem cell transplantation is highly efficient for the treatment of systemic autoimmune diseases, but its consequences for the immune system remain poorly understood. Here, we describe an optimized RNA-based technology for unbiased amplification of T cell receptor beta-chain libraries and use it to perform the first detaile...
Article
Physical, psychological, and social function in MS patients is significantly deteriorated. Quality of life profile of the patients is characterized by compression and deformation. The majority of the patients exhibit either severe or critical QoL impairment. MS patients experience a wide range of disease-related symptoms; the most frequent symptoms...
Article
4757 Increased importance should be placed on the comprehensive symptom assessment in patients with multiple myeloma to accurately document the broad range of physical and psychological disease manifestations given from the patient perspective. The new developed symptom assessment tool - Comprehensive Symptom Profile in Multiple Myeloma Patients (C...
Article
372 High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (ASCT) offers promising results in the treatment of multiple sclerosis (MS) patients. Reduced intensity conditioning regimens (mini-ASCT) is a way to improve the balance between benefits and side effects of this treatment approach. The goal of our...
Article
During the last decade high-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation (HDIT+ASCT) has been used with increasing frequency as a therapeutic option for MS patients. We aimed to study clinical outcomes in patients with different MS types after HDIT+ASCT. 156 MS patients (secondary progressive, 54; primary...
Article
2561 Comprehensive symptom assessment before and during treatment in lymphoma patients is worthwhile. We aimed to develop a new symptom assessment tool — Comprehensive Symptom Profile in Lymphoma Patients (CSP-Lym) and test its applicability to this patient population. The CSP-Lym is a self-reported tool which allows the assessment of the severity...
Article
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is a promising approach to treatment of autoimmune diseases. HDIT + auto-HSCT in multiple sclerosis (MS) patients is of special interest since there are no effective treatment methods for this disease. In this paper, we present resutts of...
Article
During the last several years high dose chemotherapy (HDCT) with autologous stem cell transplantation (auto-HSCT) has been established as a therapeutic option for multiple sclerosis (MS) patients. We report clinical and patient-reported outcomes of HDCT + auto-HSCT in a male patient affected by secondary progressive MS (EDSS 5.0 at base-line). Redu...
Article
2317 Poster Board II-294 High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) offers promising results in the treatment of multiple sclerosis (MS) patients. Reduced intensity conditioning regimens (RIC-AHSCT) is a way to improve the balance between benefits and side effects of this treatment approach....
Article
Conventional therapies do not provide satisfactory control of multiple sclerosis (MS) due to their inability to eradicate self-specific T cell clones. Recently, high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (AHSCT) was proposed as a new and promising therapy for MS patients. Taking into account the info...
Article
Conventional therapies do not provide satisfactory control of multiple sclerosis (MS) due to their inability to eradicate self-specific T cell clones. During the last decade high-dose immunosuppressive therapy (HDIT) with autologous haematopoietic stem cell transplantation (AHSCT) has been used with increasing frequency as a therapeutic option for...
Article
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is a new and promising approach to the treatment of multiple sclerosis (MS) patients because currently there are no effective treatment methods for this disease. In this article, we present results of a prospective clinical study of effica...
Article
Background: Although there is no effective cure for this disease, high-dose chemotherapy (HDCT), together with autologous hematopoietic stem cell transplantation (auto-HSCT) offers promising results in the treatment of multiple sclerosis (MS) patients.Methods: In this paper we present results of a prospective clinical study of safety and efficacy o...
Article
During the last decade immunoablative therapy with ASCT (IT+ASCT) has been used with increasing frequency as a therapeutic option for MS patients. Among a number of unanswered questions is the timing of IT+ASCT. We have identified 3 strategies of IT+ASCT depending on the stage in disease process: early, conventional and salvage/late. The goal of ou...
Article
17048 Background: This outcome measure of cancer-related symptoms was conducted in Russia in 2005–2006 to have a better understanding of the current status of symptom management among patients with advanced cancer. Specific aims of this study are to describe the prevalence of pain, fatigue, and other cancer-related symptoms among cancer patients be...
Article
During the last decade HDCT+ASCT is more often used as a therapeutic option for MS patients. The major treatment outcomes for MS patients are disease-progressive free period and improvement of patient’s quality of life (QoL). We aimed to study treatment outcomes in MS patients after early, conventional and salvage HDCT+ASCT. Thirty two patients wit...
Article
HDCT+ASCT is a new and promising therapy for MS patients. Among a number of unclear questions is the terms of conducting HDCT+ASCT. According to our concept there are 3 strategies of HDCT+ASCT depending on the terms of disease process: early, conventional and salvage. Another important consideration is that the major treatment outcomes for MS patie...
Article
The population of new ANHL patients is heterogeneous in terms of their biological parameters and the IPI scoring system is widely used to make the disease prognosis. Recently heterogeneity of ANHL patients in terms of their QoL has been shown. There are four groups of patients with the following grades of QoL impairment: none, mild, significant, an...
Article
During the last several years high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) has been established as a therapeutic option for multiple sclerosis (MS) patients. We report on the long-term effects of HDCT + ASCT in two female patients affected by secondary progressive and relapsing-remitting types of MS, respectively....
Article
Background: It is quite obvious that population of new Hodgkin’s disease (HD) patients is heterogeneous in terms of clinical characteristics. Therefore stratification of patients is necessary to select appropriate treatment regimen. It was shown that new lymphoma patient population is heterogeneous in terms of base-line QoL (Novik A et al, 2003). T...
Article
Objectives: HDCT+ASCT is a new and promising therapy for MS patients. Among a number of questions are the terms of conducting HDCT+ASCT. According to our concept there are 3 strategies of HDCT+ASCT depending on terms of disease stage: early, conventional and salvage. The aim of the research was to study clinical and quality of life (QoL) outcomes i...

Citations

... Regimen-related mortality is in the range of 1%-5% and varies with the intensity of the conditioning regimen used (Farge et al., 2010, 12). The long-term risks of aH-SCT include new secondary autoimmune diseases (Burt et al., 2021), viral reactivation such as shingles, reduced fertility in males and females, premature gonadal failure leading to menopause in females, increased incidence of metabolic syndrome and diabetes mellitus, and a risk of increased incidence of cancer (Majhail, 2017). ...
... в России успешно реализована многоцентровая проспективная наблюдательная программа «Показатели качества жизни и профиль симптомов у больных хроническим миелолейкозом на фоне лечения при резистентности или непереносимости предшествующей терапии иматинибом». Результаты данной программы, полученные в условиях реальной клинической практики, свидетельствуют об эффективности и безопасности 2-й линии терапии дазатинибом как на основании клинических данных, так и с точки зрения пациентов [26][27][28][29][30][31]. В рамках программы пациентов наблюдали в течение 1-го года терапии дазатинибом. ...
... At present the most promising results of HDIT+AHSCT have been obtained in MS patients with BEAM as a conditioning regimen [7,12,13,[22][23][24][25]. Thus, we aimed to study if reduced-intensity BEAM with consolidation therapy using Mitoxantrone is a safe and effective treatment approach for MS. ...
... в России успешно реализована многоцентровая проспективная наблюдательная программа «Показатели качества жизни и профиль симптомов у больных хроническим миелолейкозом на фоне лечения при резистентности или непереносимости предшествующей терапии иматинибом». Результаты данной программы, полученные в условиях реальной клинической практики, свидетельствуют об эффективности и безопасности 2-й линии терапии дазатинибом как на основании клинических данных, так и с точки зрения пациентов [26][27][28][29][30][31]. В рамках программы пациентов наблюдали в течение 1-го года терапии дазатинибом. ...
... Тем не менее у 15-20 % пациентов отмечаются рефрактерность к проводимой химиотера пии и развитие ранних рецидивов заболевания. В этих случаях возникает необходимость изменения подходов к лечению, применения таргетной и иммунотерапии, а также выполнения аутологичной или аллогенной транс плантации гемопоэтических стволовых клеток [4]. ...
... MS progression inevitably leads to the loss of motor function, sensitive disturbances and cognitive impairment because of the immune mediated demyelination and axon degeneration. MS is one of the most common neurological disorders, which mainly affects young adults [12], and causes gradual decrease of their quality of life [13]. Infectious organisms, most likely viruses, have long been a suspect for triggering the autoimmune response in people genetically susceptible to MS [14]. ...
... Both physicians and patients return medical questionnaires and health status updates each year at the anniversary of transplantation. 27 Patients unable to return to Seattle undergo detailed evaluations by their primary physicians following Center guidelines. Information gained from the tracking methods outlined previously and data from patient consultations to our clinical team via telephone, fax, and letter are key-entered into the Long-Term Follow-up Database. ...
... The primary goal of our study was to psychometrically validate a MDASI module specific to CML (MDASI-CML). Early-phase development of 2 other patient-reported scales to measure symptoms in CML have been reported in abstract form: the Comprehensive Symptom Profile for CML 24 and a European Organization for Research and Treatment of Cancer (EORTC) CML questionnaire. 25 Because few studies have followed health-related QOL longitudinally in patients with CML, 9,11,26 and no study has longitudinally compared symptoms related to various TKIs, our secondary goal was to explore the occurrence of symptoms reported by patients with CML over a 1-year period. ...
... Mitoxantrone in the total dose of 60-72 mg/m 2 within the first year after transplantation might be considered as a good option. At present the most promising results of HDIT+AHSCT have been obtained in MS patients with BEAM as a conditioning regimen [7,12,13,[22][23][24][25]. Thus, we aimed to study if reduced-intensity BEAM with consolidation therapy using Mitoxantrone is a safe and effective treatment approach for MS. ...
... Mitoxantrone in the total dose of 60-72 mg/m 2 within the first year after transplantation might be considered as a good option. At present the most promising results of HDIT+AHSCT have been obtained in MS patients with BEAM as a conditioning regimen [7,12,13,[22][23][24][25]. Thus, we aimed to study if reduced-intensity BEAM with consolidation therapy using Mitoxantrone is a safe and effective treatment approach for MS. ...